Dual specificity protein kinase
From Proteopedia
(Difference between revisions)
| Line 17: | Line 17: | ||
**[[1z57]] – hCLK1 kinase domain + himenialdizine – human | **[[1z57]] – hCLK1 kinase domain + himenialdizine – human | ||
| - | **[[2vag]] - hCLK1 kinase domain + indole inhibitor | + | **[[2vag]] - hCLK1 kinase domain + indole inhibitor<br /> |
| + | **[[5j1v]], [[5j1w]] – hCLK1 kinase domain + quinazoline inhibitor<br /> | ||
*CLK2 | *CLK2 | ||
| Line 41: | Line 42: | ||
**[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand | **[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand | ||
| - | **[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]] - hTTK kinase domain + inhibitor | + | **[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]], [[5ehl]], [[5eho]], [[5ehy]], [[5ei2]], [[5ei6]], [[5ei8]], [[5ap0]], [[5ap1]], [[5ap2]], [[5eh0]], [[4zeg]] - hTTK kinase domain + inhibitor |
**[[2zmc]] - hTTK kinase domain | **[[2zmc]] - hTTK kinase domain | ||
| - | **[[2zmd]] - hTTK kinase domain (mutant) + inhibitor | + | **[[2zmd]], [[5ap3]], [[5ap4]], [[5ap5]], [[5ap6]], [[5ap7]] - hTTK kinase domain (mutant) + inhibitor<br /> |
**[[3hmn]] - hTTK kinase domain + ATP | **[[3hmn]] - hTTK kinase domain + ATP | ||
| Line 51: | Line 52: | ||
**[[3hmo]] - hTTK kinase domain + staurosporine | **[[3hmo]] - hTTK kinase domain + staurosporine | ||
| - | **[[3hmp]] - hTTK kinase domain + | + | **[[3hmp]] - hTTK kinase domain + quinazoline ligand<br /> |
| + | **[[5ljj]] - hTTK kinase domain + reversine<br /> | ||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 09:55, 26 April 2017
| |||||||||||
3D structures of dual specificity protein kinase
Updated on 26-April-2017
References
- ↑ Dhanasekaran N, Premkumar Reddy E. Signaling by dual specificity kinases. Oncogene. 1998 Sep 17;17(11 Reviews):1447-55. PMID:9779990 doi:http://dx.doi.org/10.1038/sj.onc.1202251
- ↑ Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U, Avanzi N, Bertrand JA, Bossi RT, Pesenti E, Galvani A, Isacchi A, Colotta F, Donati D, Moll J. Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase. Cancer Res. 2010 Dec 15;70(24):10255-64. PMID:21159646 doi:10.1158/0008-5472.CAN-10-2101
